Genetic Predisposition to Parkinson’s Disease and Cancer

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 15, 9 Issues, 2015

Download PDF Flyer

Current Cancer Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 211 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.522
5 - Year: 3.572

Genetic Predisposition to Parkinson’s Disease and Cancer

Current Cancer Drug Targets, 14(3): 310-321.

Author(s): Zhiming Li, Qing Lin, Qilin Ma, Congxia Lu and Chi-Meng Tzeng.

Affiliation: School of Pharmaceutical Sciences, Xiamen University, Xiamen 361005, Fujian, China.


Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.


Cancer, genes, parkinson’s disease, pathways.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 3
First Page: 310
Last Page: 321
Page Count: 12
DOI: 10.2174/1568009614666140312145936

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science